Plurihormonal PIT1-lineage pituitary neuroendocrine tumors: a clinicopathological study.
10.3760/cma.j.cn112151-20230216-00137
- Author:
Z J DUAN
1
;
J FENG
1
;
H Q ZHAO
2
;
H D WANG
3
;
Q P GUI
1
;
X F ZHANG
4
;
Z MA
1
;
Z J HU
1
;
L XIANG
1
;
X L QI
1
Author Information
1. Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China.
2. Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China.
3. Department of Neurology, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China.
4. Department of Radiology, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Neuroendocrine Tumors;
Pituitary Neoplasms/pathology*;
Pituitary Hormones;
Growth Hormone/metabolism*;
Keratins
- From:
Chinese Journal of Pathology
2023;52(10):1017-1024
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinicopathological characteristics of plurihormonal PIT1-lineage pituitary neuroendocrine tumors. Methods: Forty-eight plurihormonal PIT1-lineage tumors were collected between January 2018 and April 2022 from the pathological database of Sanbo Brain Hospital, Capital Medical University. The related clinical and imaging data were retrieved. H&E, immunohistochemical and special stains were performed. Results: Out of the 48 plurihormonal PIT1-lineage tumors included, 13 cases were mature PIT1-lineage tumors and 35 cases were immature PIT1-lineage tumors. There were some obvious clinicopathological differences between the two groups. Clinically, the mature plurihormonal PIT1-lineage tumor mostly had endocrine symptoms due to increased hormone production, while a small number of immature PIT1-lineage tumors had endocrine symptoms accompanied by low-level increased serum pituitary hormone; patients with the immature PIT1-lineage tumors were younger than the mature PIT1-lineage tumors; the immature PIT1-lineage tumors were larger in size and more likely invasive in imaging. Histopathologically, the mature PIT1-lineage tumors were composed of large eosinophilic cells with high proportion of growth hormone expression, while the immature PIT1-lineage tumors consisted of chromophobe cells with a relatively higher expression of prolactin; the mature PIT1-lineage tumors had consistently diffuse cytoplasmic positive staining for keratin, while the immature PIT1-lineage tumors had various expression for keratin; the immature PIT1-lineage tumors showed more mitotic figures and higher Ki-67 proliferation index; in addition, 25.0% (12/48) of PIT1-positive plurihormonal tumors showed abnormal positive staining for gonadotropin hormones. There was no significant difference in the progression-free survival between the two groups (P=0.648) by Kaplan-Meier analysis. Conclusions: Plurihormonal PIT1-lineage tumor belongs to a rare type of PIT1-lineage pituitary neuroendocrine tumors, most of which are of immature lineage. Clinically increased symptoms owing to pituitary hormone secretion, histopathologically increased number of eosinophilic tumor cells with high proportion of growth hormone expression, diffusely cytoplasmic keratin staining and low proliferative activity can help differentiate the mature plurihormonal PIT1-lineage tumors from the immature PIT1-lineage tumors. The immature PIT1-lineage tumors have more complicated clinicopathological characteristics.
